Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer
BACKGROUND: Olaparib is an oral inhibitor of polyadenosine 5’-diphosphoribose polymerization (PARP) that has previously shown signs of activity in patients with BRCA mutations and pancreatic ductal adenocarcinoma (PDAC). PATIENTS AND METHODS: In this phase 1 dose-escalation trial in patients with un...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546463/ https://www.ncbi.nlm.nih.gov/pubmed/28454122 http://dx.doi.org/10.18632/oncotarget.17237 |
_version_ | 1783255552565968896 |
---|---|
author | Yarchoan, Mark Myzak, Melinda C. Johnson, Burles A. De Jesus-Acosta, Ana Le, Dung T. Jaffee, Elizabeth M. Azad, Nilofer S. Donehower, Ross C. Zheng, Lei Oberstein, Paul E. Fine, Robert L. Laheru, Daniel A. Goggins, Michael |
author_facet | Yarchoan, Mark Myzak, Melinda C. Johnson, Burles A. De Jesus-Acosta, Ana Le, Dung T. Jaffee, Elizabeth M. Azad, Nilofer S. Donehower, Ross C. Zheng, Lei Oberstein, Paul E. Fine, Robert L. Laheru, Daniel A. Goggins, Michael |
author_sort | Yarchoan, Mark |
collection | PubMed |
description | BACKGROUND: Olaparib is an oral inhibitor of polyadenosine 5’-diphosphoribose polymerization (PARP) that has previously shown signs of activity in patients with BRCA mutations and pancreatic ductal adenocarcinoma (PDAC). PATIENTS AND METHODS: In this phase 1 dose-escalation trial in patients with unresectable PDAC, we determined the maximum tolerated dose (MTD) of olaparib (tablet formulation) in combination with irinotecan 70 mg/m(2) on days 1 and 8 and cisplatin 25 mg/m(2) on days 1 and 8 of a 28-day cycle (olaparib plus IC). We then studied the safety and tolerability of adding mitomycin C 5 mg/m(2) on day 1 to this regimen (olaparib plus ICM). RESULTS: 18 patients with unresectable PDAC were enrolled. The MTD of olaparib plus IC was olaparib 100 mg twice-daily on days 1 and 8. The addition of mitomycin C to this dose level was not tolerated. Grade ≥3 drug-related adverse events (AEs) were encountered in 16 patients (89%). The most common grade ≥3 drug-related toxicities included neutropenia (89%), lymphopenia (72%), and anemia (22%). Two patients (11%), both of whom had remained on study for more than 12 cycles, developed drug-related myelodysplastic syndrome (MDS). The objective response rate (ORR) for all evaluable patients was 23%. One patient who carried a deleterious germline BRCA2 mutation had a durable clinical response lasting more than four years, but died from complications of treatment-related MDS. CONCLUSIONS: Olaparib had substantial toxicity when combined with IC or ICM in patients with PDAC, and this treatment combination did not have an acceptable risk/benefit profile for further study. However, durable clinical responses were observed in a subset of patients and further clinical investigation of PARP inhibitors in PDAC is warranted. TRIAL REGISTRATION: This clinical trial was registered on ClinicalTrials.gov as NCT01296763. |
format | Online Article Text |
id | pubmed-5546463 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-55464632017-08-23 Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer Yarchoan, Mark Myzak, Melinda C. Johnson, Burles A. De Jesus-Acosta, Ana Le, Dung T. Jaffee, Elizabeth M. Azad, Nilofer S. Donehower, Ross C. Zheng, Lei Oberstein, Paul E. Fine, Robert L. Laheru, Daniel A. Goggins, Michael Oncotarget Research Paper BACKGROUND: Olaparib is an oral inhibitor of polyadenosine 5’-diphosphoribose polymerization (PARP) that has previously shown signs of activity in patients with BRCA mutations and pancreatic ductal adenocarcinoma (PDAC). PATIENTS AND METHODS: In this phase 1 dose-escalation trial in patients with unresectable PDAC, we determined the maximum tolerated dose (MTD) of olaparib (tablet formulation) in combination with irinotecan 70 mg/m(2) on days 1 and 8 and cisplatin 25 mg/m(2) on days 1 and 8 of a 28-day cycle (olaparib plus IC). We then studied the safety and tolerability of adding mitomycin C 5 mg/m(2) on day 1 to this regimen (olaparib plus ICM). RESULTS: 18 patients with unresectable PDAC were enrolled. The MTD of olaparib plus IC was olaparib 100 mg twice-daily on days 1 and 8. The addition of mitomycin C to this dose level was not tolerated. Grade ≥3 drug-related adverse events (AEs) were encountered in 16 patients (89%). The most common grade ≥3 drug-related toxicities included neutropenia (89%), lymphopenia (72%), and anemia (22%). Two patients (11%), both of whom had remained on study for more than 12 cycles, developed drug-related myelodysplastic syndrome (MDS). The objective response rate (ORR) for all evaluable patients was 23%. One patient who carried a deleterious germline BRCA2 mutation had a durable clinical response lasting more than four years, but died from complications of treatment-related MDS. CONCLUSIONS: Olaparib had substantial toxicity when combined with IC or ICM in patients with PDAC, and this treatment combination did not have an acceptable risk/benefit profile for further study. However, durable clinical responses were observed in a subset of patients and further clinical investigation of PARP inhibitors in PDAC is warranted. TRIAL REGISTRATION: This clinical trial was registered on ClinicalTrials.gov as NCT01296763. Impact Journals LLC 2017-04-19 /pmc/articles/PMC5546463/ /pubmed/28454122 http://dx.doi.org/10.18632/oncotarget.17237 Text en Copyright: © 2017 Yarchoan et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Yarchoan, Mark Myzak, Melinda C. Johnson, Burles A. De Jesus-Acosta, Ana Le, Dung T. Jaffee, Elizabeth M. Azad, Nilofer S. Donehower, Ross C. Zheng, Lei Oberstein, Paul E. Fine, Robert L. Laheru, Daniel A. Goggins, Michael Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer |
title | Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer |
title_full | Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer |
title_fullStr | Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer |
title_full_unstemmed | Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer |
title_short | Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer |
title_sort | olaparib in combination with irinotecan, cisplatin, and mitomycin c in patients with advanced pancreatic cancer |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546463/ https://www.ncbi.nlm.nih.gov/pubmed/28454122 http://dx.doi.org/10.18632/oncotarget.17237 |
work_keys_str_mv | AT yarchoanmark olaparibincombinationwithirinotecancisplatinandmitomycincinpatientswithadvancedpancreaticcancer AT myzakmelindac olaparibincombinationwithirinotecancisplatinandmitomycincinpatientswithadvancedpancreaticcancer AT johnsonburlesa olaparibincombinationwithirinotecancisplatinandmitomycincinpatientswithadvancedpancreaticcancer AT dejesusacostaana olaparibincombinationwithirinotecancisplatinandmitomycincinpatientswithadvancedpancreaticcancer AT ledungt olaparibincombinationwithirinotecancisplatinandmitomycincinpatientswithadvancedpancreaticcancer AT jaffeeelizabethm olaparibincombinationwithirinotecancisplatinandmitomycincinpatientswithadvancedpancreaticcancer AT azadnilofers olaparibincombinationwithirinotecancisplatinandmitomycincinpatientswithadvancedpancreaticcancer AT donehowerrossc olaparibincombinationwithirinotecancisplatinandmitomycincinpatientswithadvancedpancreaticcancer AT zhenglei olaparibincombinationwithirinotecancisplatinandmitomycincinpatientswithadvancedpancreaticcancer AT obersteinpaule olaparibincombinationwithirinotecancisplatinandmitomycincinpatientswithadvancedpancreaticcancer AT finerobertl olaparibincombinationwithirinotecancisplatinandmitomycincinpatientswithadvancedpancreaticcancer AT laherudaniela olaparibincombinationwithirinotecancisplatinandmitomycincinpatientswithadvancedpancreaticcancer AT gogginsmichael olaparibincombinationwithirinotecancisplatinandmitomycincinpatientswithadvancedpancreaticcancer |